TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31006038

Group type: EXPERIMENTAL
Intervention: Sunitinib 15 mg/m2 per day, 4-weeks-on/2-weeks-off (schedule 4/2), with intra-patient dose escalation to 22.5 and subsequently 30 mg/m2 based on tolerability.
Number of subjects: 6
Study: 30061768

Group type: EXPERIMENTAL
Intervention: Nanosil mouthwash (oral decontamination program performed three times a day for five days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chlorhexidine 0.12% (oral decontamination program performed three times a day for five days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nanosil mouthwash
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chlorhexidine 0.12%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nanosil mouthwash and Chlorhexidine 0.12%
Number of subjects: 80
Study: 27185721

Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac
Number of subjects: 608

Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608

Group type: COMPARATOR
Intervention: HPβCD-diclofenac vs Placebo
Number of subjects: 608
Study: 25337871

Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 21115

Group type: COMPARATOR
Intervention: Open Repair
Number of subjects: 21115

Group type: COMPARATOR
Intervention: Comparison of EVAR to Open Repair
Number of subjects: 21115

Group type: COMPARATOR
Intervention: Men vs Women
Number of subjects: 21115

Group type: COMPARATOR
Intervention: NSQIP cohort vs OVER trial
Number of subjects: 21115

Group type: EXPERIMENTAL
Intervention: Temporal trends in EVAR usage
Number of subjects: 21115

Group type: COMPARATOR
Intervention: Change in perioperative mortality over time
Number of subjects: 21115
Study: 21811769

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Monarc sling
Number of subjects: 87

Group type: COMPARATOR
Intervention: Both groups (TVT and Monarc)
Number of subjects: 87
Study: 19884037

Group type: EXPERIMENTAL
Intervention: Cervical spine manual therapy (lateral glide)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Manual contact intervention
Number of subjects: 39
Study: 17335465

Group type: EXPERIMENTAL
Intervention: Lamotrigine 25 mg twice daily
Number of subjects: 53

Group type: COMPARATOR
Intervention: Amitriptyline 10, 25, and 50 mg at night-time
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both treatments (Lamotrigine and Amitriptyline)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 53
Study: 15765335

Group type: EXPERIMENTAL
Intervention: Bright-light measurement
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Room-light measurement
Number of subjects: 136

Group type: COMPARATOR
Intervention: Gestalt judgment
Number of subjects: 136
Study: 11877357

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 728

Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 728
Study: 10344555

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (Mitoxantrone: 45 mg/m2, Cyclophosphamide: 120 mg/kg, Melphalan: 140 mg/m2)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard chemotherapy (conventional chemotherapy)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 61
Study: 8944393

Group type: EXPERIMENTAL
Intervention: meta-chlorophenylpiperazine (mCPP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 1758944

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Support therapy
Number of subjects: 110
Study: 7057858

Group type: EXPERIMENTAL
Intervention: Continuing education packages covering clinical problems
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no continuing education packages)
Number of subjects: 16
Study: 31493677

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 145
Study: 29758255

Group type: EXPERIMENTAL
Intervention: Traditional method (T)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Simplified method (S)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Both methods (T and S)
Number of subjects: 104
Study: 26577683

Group type: EXPERIMENTAL
Intervention: Twice-daily budesonide 2mg foam
Number of subjects: 165
Study: 24480430

Group type: EXPERIMENTAL
Intervention: PBSC group received subcutaneous G-CSF injections (15 µg/kg/day) for 5 consecutive days, followed by stereotaxic implantation of 3-8 × 10(6) CD34(+) immunosorted PBSCs.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PBSC group (details as above).
Number of subjects: 30
Study: 23285483

Group type: EXPERIMENTAL
Intervention: Far infrared emitting plaster
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 60
Study: 20807120

Group type: EXPERIMENTAL
Intervention: Intermittent high-intensity exercise (IHE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Moderate-intensity exercise (MOD)
Number of subjects: 8
Study: 17598500

Group type: EXPERIMENTAL
Intervention: Comprehensive, population-based, organised cervical cancer prevention programmes integrating cervical screening with new technologies and vaccines
Number of subjects: 0
Study: 15768872

Group type: EXPERIMENTAL
Intervention: Qingxin capsule (QXC)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: QXC plus captopril
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: QXC
Number of subjects: 98
Study: 12191719

Group type: EXPERIMENTAL
Intervention: Psilocybin (PY) at 212+/‐25 microg/kg body weight
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Addition of beta‐glucuronidase to urine samples
Number of subjects: 8
Study: 11256036

Group type: EXPERIMENTAL
Intervention: 100 micrograms levothyroxine + 100 micrograms iodide
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 75 micrograms levothyroxine + 150 micrograms iodide
Number of subjects: 44
Study: 9505778

Group type: EXPERIMENTAL
Intervention: Pirenzepine 25 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Pirenzepine 25 mg + Ranitidine 75 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 7797216

Group type: EXPERIMENTAL
Intervention: Sitting posture (Group I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lying down posture (Group II)
Number of subjects: 0
Study: 3134082

Group type: EXPERIMENTAL
Intervention: Paranormal healing by laying on of hands
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Paranormal healing at a distance
Number of subjects: 115

Group type: COMPARATOR
Intervention: No paranormal healing (control)
Number of subjects: 115
Study: 19585923

Group type: EXPERIMENTAL
Intervention: Spirituality counseling
Number of subjects: 31

Group type: COMPARATOR
Intervention: Dietitian-only arm (Control)
Number of subjects: 31
Study: 343743

Group type: EXPERIMENTAL
Intervention: Naproxen 250 mg twice a day
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg taken at bedtime
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg four times a day
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Naproxen (single daily dose)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 132
Study: 30702366

Group type: EXPERIMENTAL
Intervention: Resisted sled sprinting (RSS) at a sled load of 30% body mass for a total program running distance of 800 m
Number of subjects: 13

Group type: COMPARATOR
Intervention: Unresisted sprinting (URS) for the same distance of 800 m
Number of subjects: 13
Study: 30073267

Group type: EXPERIMENTAL
Intervention: Cochlear Implants (CIs)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal Hearing (NH)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Auditory degradation
Number of subjects: 46
Study: 27614164

Group type: EXPERIMENTAL
Intervention: Postoperative whole breast radiotherapy (RT)
Number of subjects: 1187

Group type: COMPARATOR
Intervention: No local treatment (Control)
Number of subjects: 1187
Study: 23873579

Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting stent (Yukon Choice)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Polymer-based paclitaxel-eluting stent (Taxus Liberté)
Number of subjects: 240
Study: 22420471

Group type: EXPERIMENTAL
Intervention: Presence of intratumoral CD8+ tumor infiltrating lymphocytes
Number of subjects: 3403
Study: 19473823

Group type: EXPERIMENTAL
Intervention: 8-week moderate-intensity aerobic training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 24
Study: 17356963

Group type: EXPERIMENTAL
Intervention: EBM educational intervention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medication databases
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Utilization of pre-appraised resources
Number of subjects: 30
Study: 15687448

Group type: EXPERIMENTAL
Intervention: PI-containing combination therapy
Number of subjects: 489
Study: 12351435

Group type: EXPERIMENTAL
Intervention: Troglitazone (600 mg/day) for 3 months
Number of subjects: 27
Study: 10072479

Group type: EXPERIMENTAL
Intervention: 50 mg thioctic acid (TA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 mg thioctic acid (TA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled plasma analysis
Number of subjects: 0
Study: 7552589

Group type: COMPARATOR
Intervention: Carbohydrate intake of 8 g/kg/day (5.5 mg/kg/minute)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carbohydrate intake of 12 g/kg/day (8.3 mg/kg/minute)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both carbohydrate intakes
Number of subjects: 20
Study: 2323402

Group type: EXPERIMENTAL
Intervention: Participation in the family planning‐based outreach program
Number of subjects: 536

Group type: COMPARATOR
Intervention: No participation in the family planning‐based outreach program (Control)
Number of subjects: 536
Study: 6245145

Group type: EXPERIMENTAL
Intervention: mecillinam
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: trimethoprim‐sulfamethoxazole
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study: 31464626

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) integrated treatment program including tripterygium glycosides (TGs), tanshinone IIa sodium sulfonate injection, and Chinese herbs based on syndrome differentiation
Number of subjects: 500

Group type: COMPARATOR
Intervention: Benazepril hydrochloride tablets, low molecular weight heparin calcium injection, dipyridamole tablets, and a Chinese medicine placebo
Number of subjects: 500

Group type: COMPARATOR
Intervention: Benazepril hydrochloride tablets, low molecular weight heparin calcium injection, dipyridamole tablets, a Chinese medicine placebo, and prednisone
Number of subjects: 500
Study: 28044436

Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement program (8 weeks, including education, skills training, phone counseling, and self-management records)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (pressure ulcer prevention information booklet)
Number of subjects: 47
Study: 24976525

Group type: EXPERIMENTAL
Intervention: BMS + DEB
Number of subjects: 85

Group type: COMPARATOR
Intervention: BMS
Number of subjects: 85
Study: 25244414

Group type: EXPERIMENTAL
Intervention: Probiotic therapy (Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus rhamnosus, and Streptococcus thermophilus) for 4 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 21523344

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19652619

Group type: EXPERIMENTAL
Intervention: 16-week group exercise program
Number of subjects: 40
Study: 17763226

Group type: EXPERIMENTAL
Intervention: Preoperative pelvic floor muscle training (PFMT) including a 1‐h individual lesson, three 1‐h group lessons, and a home training programme.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 58

Group type: COMPARATOR
Intervention: Both groups received verbal instructions regarding PFMT postoperatively.
Number of subjects: 58
Study: 15167471

Group type: EXPERIMENTAL
Intervention: Gray-colored MTA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Off-white-colored MTA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Positive control (not specified)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Negative control (not specified)
Number of subjects: 40
Study: 12040670

Group type: EXPERIMENTAL
Intervention: Concurrent chemo-radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus surgical salvage treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 0
Study: 12568173

Group type: EXPERIMENTAL
Intervention: Abbott Safeset blood conserving arterial line system
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional indwelling arterial line system
Number of subjects: 99
Study: 7553996

Group type: EXPERIMENTAL
Intervention: 1 MAC sevoflurane (S1)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 2 MAC sevoflurane (S2)
Number of subjects: 38

Group type: COMPARATOR
Intervention: 1 MAC halothane (H1)
Number of subjects: 38

Group type: COMPARATOR
Intervention: 2 MAC halothane (H2)
Number of subjects: 38
Study: 2212088

Group type: EXPERIMENTAL
Intervention: Listerine (LA)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Peridex (PX)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Hydroalcohol control
Number of subjects: 124
Study: 738832

Group type: EXPERIMENTAL
Intervention: Activation of unconscious fantasies of symbiotic gratification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laboratory experiments with double-blind procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinically based reports
Number of subjects: 0
Study: 29981566

Group type: EXPERIMENTAL
Intervention: Prefilled syringe
Number of subjects: 113

Group type: COMPARATOR
Intervention: EpiPen
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study: 27150635

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus plantarum 299 and Bifidobacterium infantis Cure 21)
Number of subjects: 32
Study: 25363789

Group type: EXPERIMENTAL
Intervention: Patient-targeted in-patient education (group 2)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard education (group 1)
Number of subjects: 198
Study: 22392456

Group type: EXPERIMENTAL
Intervention: Citalopram (first-step treatment)
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion, sertraline, or extended-release venlafaxine (second-step treatment)
Number of subjects: 727
Study: 20515209

Group type: EXPERIMENTAL
Intervention: IPSY (Information + Psychosocial Competence = Protection)
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: IPSY
Number of subjects: 1484

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1484
Study: 18036121

Group type: EXPERIMENTAL
Intervention: New leaflet
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control leaflet
Number of subjects: 126
Study: 16136287

Group type: EXPERIMENTAL
Intervention: Quixil sealant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Kaltostat (control)
Number of subjects: 20
Study: 12036528

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Verapamil withdrawal
Number of subjects: 14
Study: 10207807

Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Control group (Cirrhotic type C patients not receiving interferon)
Number of subjects: 1148
Study: 7599914

Group type: EXPERIMENTAL
Intervention: celiprolol
Number of subjects: 23

Group type: COMPARATOR
Intervention: control group
Number of subjects: 23
Study: 2221406

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 1178

Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 1178
Study: 93297

Group type: EXPERIMENTAL
Intervention: gamma-globulin 16 Merieux (1 ml/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 31118057

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 4 J/cm2
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 97
Study: 28168199

Group type: EXPERIMENTAL
Intervention: Capsule Endoscopy (CE)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (139 patients who underwent CE)
Number of subjects: 31
Study: 26736728

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnetic seizure therapy (MST)
Number of subjects: 0
Study: 23807528

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg daily)
Number of subjects: 119
Study: 22046394

Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine (TDF-FTC), n = 178
Number of subjects: 303

Group type: COMPARATOR
Intervention: Abacavir-lamivudine (ABC-3TC), n = 179
Number of subjects: 303
Study: 19934423

Group type: EXPERIMENTAL
Intervention: ACLS with intravenous drug administration
Number of subjects: 851

Group type: COMPARATOR
Intervention: ACLS without intravenous drug administration
Number of subjects: 851
Study: 16476841

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO), 10,000 U three times weekly s.c.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study: 12771010

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study: 10677157

Group type: EXPERIMENTAL
Intervention: Heparin group (maintaining a whole blood heparin concentration of 3 mg/kg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: ACT group (maintaining an ACT >400 s)
Number of subjects: 2
Study: 9116534

Group type: EXPERIMENTAL
Intervention: Guideline certification program for cesarean section deliveries
Number of subjects: 366246

Group type: EXPERIMENTAL
Intervention: Repeat cesareans
Number of subjects: 366246

Group type: EXPERIMENTAL
Intervention: Primary cesareans
Number of subjects: 366246

Group type: COMPARATOR
Intervention: Guideline implementation date
Number of subjects: 366246
Study: 8157720

Group type: EXPERIMENTAL
Intervention: Dietary energy restriction at 10 Cal/kg lean body mass.day
Number of subjects: 7
Study: 3345633

Group type: EXPERIMENTAL
Intervention: Post-absorptive state in healthy subjects
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fed state in healthy subjects
Number of subjects: 28

Group type: COMPARATOR
Intervention: Patients with muscular dystrophy in fed state
Number of subjects: 28

Group type: COMPARATOR
Intervention: Patients with myotonic dystrophy in post-absorptive state
Number of subjects: 28
Study: 29758175

Group type: EXPERIMENTAL
Intervention: Verbal instructions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Written instructions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Verbal plus written instructions
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (verbal instructions)
Number of subjects: 120
Study: 24521107

Group type: EXPERIMENTAL
Intervention: Oxantel pamoate (20 mg/kg) plus albendazole (400 mg)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Mebendazole (500 mg)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Albendazole (400 mg)
Number of subjects: 458
Study: 22422104

Group type: COMPARATOR
Intervention: Spousal caregiver
Number of subjects: 374

Group type: COMPARATOR
Intervention: Non-spousal caregiver
Number of subjects: 374
Study: 20715734

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (target glycaemic control: 4.4 to 6.1 mmol/l)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Conventional insulin therapy (target control: 10.0 to 11.1 mmol/l)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Glycaemic fluctuation (mean difference between highest and lowest daily blood glucose)
Number of subjects: 523
Study: 18023151

Group type: EXPERIMENTAL
Intervention: Single oral dose of parenteral veterinary preparation of ivermectin
Number of subjects: 42

Group type: COMPARATOR
Intervention: 7-day course of oral albendazole 800 mg daily
Number of subjects: 42
Study: 15738029

Group type: EXPERIMENTAL
Intervention: Late transabdominal chorionic villus sampling (CVS)
Number of subjects: 3698

Group type: COMPARATOR
Intervention: Early amniocentesis
Number of subjects: 3698

Group type: EXPERIMENTAL
Intervention: Early amniocentesis with no placental penetration
Number of subjects: 3698

Group type: EXPERIMENTAL
Intervention: Early amniocentesis with placental penetration
Number of subjects: 3698

Group type: EXPERIMENTAL
Intervention: Late CVS
Number of subjects: 3698
Study: 12973169

Group type: EXPERIMENTAL
Intervention: Bacterial filters (BF)
Number of subjects: 230

Group type: COMPARATOR
Intervention: No bacterial filters (Control)
Number of subjects: 230
Study: 10619727

Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg) daily for 14 days
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study: 8949765

Group type: EXPERIMENTAL
Intervention: Fast neutron therapy alone or in combination with photons
Number of subjects: 906

Group type: COMPARATOR
Intervention: Photons only
Number of subjects: 906
Study: 2023603

Group type: EXPERIMENTAL
Intervention: f/VT ratio
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Plmax
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CROP index
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: VE
Number of subjects: 100
Study: 7282596

Group type: EXPERIMENTAL
Intervention: Vitamin E (100 or 400 units/day orally for 4 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Warfarin (0.01 mg/100 g, IP) with vitamin E (1000 units/kg IM for 7 days) in rats
Number of subjects: 12
Study: 31785442

Group type: EXPERIMENTAL
Intervention: Gait disorder
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Myoclonus
Number of subjects: 160
Study: 31303750

Group type: EXPERIMENTAL
Intervention: Home-based cognitive intervention (HCI) for 12 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57